Transfusions in people with haematological malignancies – Results of a repeat UK national comparative audit with improvement in practice

Red cell and platelet transfusions are essential in the management of people with haematological malignancies and bone marrow failure disorders. Up to 65% of platelet components and 25% of red cell components issued are given to haematology patients, and most are used in the elderly. As the UK popul...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: Estcourt, L, Karakantza, M, Grant-Casey, J, Lowe, D, Birchall, J
Materyal Türü: Conference item
Baskı/Yayın Bilgisi: Wiley 2018
_version_ 1826282517132476416
author Estcourt, L
Karakantza, M
Grant-Casey, J
Lowe, D
Birchall, J
author_facet Estcourt, L
Karakantza, M
Grant-Casey, J
Lowe, D
Birchall, J
author_sort Estcourt, L
collection OXFORD
description Red cell and platelet transfusions are essential in the management of people with haematological malignancies and bone marrow failure disorders. Up to 65% of platelet components and 25% of red cell components issued are given to haematology patients, and most are used in the elderly. As the UK population is ageing, with a predicted doubling in people aged 85 years by 2041, only using red cell and platelet transfusion to those likely to benefit is imperative to minimise side effects, limit costs, and maintain the blood supply.
first_indexed 2024-03-07T00:45:03Z
format Conference item
id oxford-uuid:8456ad73-2d5a-4f41-8a8c-a689d45a214e
institution University of Oxford
last_indexed 2024-03-07T00:45:03Z
publishDate 2018
publisher Wiley
record_format dspace
spelling oxford-uuid:8456ad73-2d5a-4f41-8a8c-a689d45a214e2022-03-26T21:50:31ZTransfusions in people with haematological malignancies – Results of a repeat UK national comparative audit with improvement in practiceConference itemhttp://purl.org/coar/resource_type/c_c94fuuid:8456ad73-2d5a-4f41-8a8c-a689d45a214eSymplectic Elements at OxfordWiley2018Estcourt, LKarakantza, MGrant-Casey, JLowe, DBirchall, JRed cell and platelet transfusions are essential in the management of people with haematological malignancies and bone marrow failure disorders. Up to 65% of platelet components and 25% of red cell components issued are given to haematology patients, and most are used in the elderly. As the UK population is ageing, with a predicted doubling in people aged 85 years by 2041, only using red cell and platelet transfusion to those likely to benefit is imperative to minimise side effects, limit costs, and maintain the blood supply.
spellingShingle Estcourt, L
Karakantza, M
Grant-Casey, J
Lowe, D
Birchall, J
Transfusions in people with haematological malignancies – Results of a repeat UK national comparative audit with improvement in practice
title Transfusions in people with haematological malignancies – Results of a repeat UK national comparative audit with improvement in practice
title_full Transfusions in people with haematological malignancies – Results of a repeat UK national comparative audit with improvement in practice
title_fullStr Transfusions in people with haematological malignancies – Results of a repeat UK national comparative audit with improvement in practice
title_full_unstemmed Transfusions in people with haematological malignancies – Results of a repeat UK national comparative audit with improvement in practice
title_short Transfusions in people with haematological malignancies – Results of a repeat UK national comparative audit with improvement in practice
title_sort transfusions in people with haematological malignancies results of a repeat uk national comparative audit with improvement in practice
work_keys_str_mv AT estcourtl transfusionsinpeoplewithhaematologicalmalignanciesresultsofarepeatuknationalcomparativeauditwithimprovementinpractice
AT karakantzam transfusionsinpeoplewithhaematologicalmalignanciesresultsofarepeatuknationalcomparativeauditwithimprovementinpractice
AT grantcaseyj transfusionsinpeoplewithhaematologicalmalignanciesresultsofarepeatuknationalcomparativeauditwithimprovementinpractice
AT lowed transfusionsinpeoplewithhaematologicalmalignanciesresultsofarepeatuknationalcomparativeauditwithimprovementinpractice
AT birchallj transfusionsinpeoplewithhaematologicalmalignanciesresultsofarepeatuknationalcomparativeauditwithimprovementinpractice